Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

787 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune Checkpoint Blockade for Breast Cancer.
Swoboda A, Nanda R. Swoboda A, et al. Among authors: nanda r. Cancer Treat Res. 2018;173:155-165. doi: 10.1007/978-3-319-70197-4_10. Cancer Treat Res. 2018. PMID: 29349763 Free PMC article. Review.
Advances in breast cancer: pathways to personalized medicine.
Olopade OI, Grushko TA, Nanda R, Huo D. Olopade OI, et al. Among authors: nanda r. Clin Cancer Res. 2008 Dec 15;14(24):7988-99. doi: 10.1158/1078-0432.CCR-08-1211. Clin Cancer Res. 2008. PMID: 19088015 Free PMC article. Review.
Phase II trial of temsirolimus in patients with metastatic breast cancer.
Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ. Fleming GF, et al. Among authors: nanda r. Breast Cancer Res Treat. 2012 Nov;136(2):355-63. doi: 10.1007/s10549-011-1910-7. Epub 2012 Jan 13. Breast Cancer Res Treat. 2012. PMID: 22245973 Free PMC article. Clinical Trial.
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.
Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF. Ma CX, et al. Among authors: nanda r. Breast Cancer Res Treat. 2013 May;139(1):145-53. doi: 10.1007/s10549-013-2528-8. Epub 2013 Apr 19. Breast Cancer Res Treat. 2013. PMID: 23605083 Free PMC article. Clinical Trial.
Immune Checkpoint Inhibitor Therapy in Breast Cancer.
Santa-Maria CA, Nanda R. Santa-Maria CA, et al. Among authors: nanda r. J Natl Compr Canc Netw. 2018 Oct;16(10):1259-1268. doi: 10.6004/jnccn.2018.7046. J Natl Compr Canc Netw. 2018. PMID: 30323094 Review.
Atezolizumab for the treatment of breast cancer.
Reddy SM, Carroll E, Nanda R. Reddy SM, et al. Among authors: nanda r. Expert Rev Anticancer Ther. 2020 Mar;20(3):151-158. doi: 10.1080/14737140.2020.1732211. Epub 2020 Feb 27. Expert Rev Anticancer Ther. 2020. PMID: 32067545 Review.
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
O'Donnell PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, Nath A, Huo D, Fleming GF, Ingle JN, Abramson VG, Morrow PK, Storniolo AM, Forero A, Van Poznak C, Liu MC, Chang JC, Merkel DE, Peppercorn JM, Rugo HS, Dees EC, Hahn OM, Hoffman PC, Rosner GL, Huang RS, Ratain MJ, Cox N, Olopade OI, Wolff AC, Dolan ME, Nanda R; Translational Breast Cancer Research Consortium (TBCRC). O'Donnell PH, et al. Among authors: nanda r. Breast Cancer Res Treat. 2020 Jun;181(3):623-633. doi: 10.1007/s10549-020-05603-8. Epub 2020 May 6. Breast Cancer Res Treat. 2020. PMID: 32378051
Racial disparities in survival outcomes among breast cancer patients by molecular subtypes.
Zhao F, Copley B, Niu Q, Liu F, Johnson JA, Sutton T, Khramtsova G, Sveen E, Yoshimatsu TF, Zheng Y, Ibraheem A, Jaskowiak N, Nanda R, Fleming GF, Olopade OI, Huo D. Zhao F, et al. Among authors: nanda r. Breast Cancer Res Treat. 2021 Feb;185(3):841-849. doi: 10.1007/s10549-020-05984-w. Epub 2020 Oct 27. Breast Cancer Res Treat. 2021. PMID: 33111220 Free PMC article.
787 results